Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Blood

Volumn 114, Issue 12, 2009, Pages 2439-2447

  Heinen, Stefan ^a   Hartmann, Andrea ^a   Lauer, Nadine ^a   Wiehl, Ulrike ^a   Dahse, Hans Martin ^a   Schirmer, Sylvia ^a   Gropp, Katharina ^a   Enghardt, Tina ^a   Wallich, Reinhard ^b   Hälbich, Steffi ^a   Mihlan, Michael ^a   Schlötzer Schrehardt, Ursula ^c   Zipfel, Peter F ^a,d   Skerka, Christine ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT C5 CONVERTASE; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; FACTOR H RELATED PROTEIN 1; PLASMA PROTEIN; UNCLASSIFIED DRUG; CFHR1 PROTEIN, HUMAN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H, HUMAN; COMPLEMENT FACTOR I;

AGED; ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; INTROSPECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOPRECIPITATION; KIDNEY; METABOLISM; PHYSIOLOGY; RETINA; SHEEP; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; CELLS, CULTURED; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT C3D; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; KIDNEY; MICROSCOPY, CONFOCAL; RETINA; SHEEP; UMBILICAL VEINS;

EID: 70349441306     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205641     Document Type: Article

References (39)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:97-216.
2. Walport MJ. Complement: first of two parts. N Engl J Med. 2001(14);344:1058-1066.
3. Walport MJ. Complement: second of two parts. N Engl J Med. 2001(15);344:1140-1144.
4. Rawal N, Pangburn MK. Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol. 2001(3);166:2635-2642. (Pubitemid 32173502)
5. Morgan BP, Harris CL. Complement Regulatory Proteins. San Diego, CA: Academic Press; 1999.
6. Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006(1-2);43:97-106. (Pubitemid 41021526)
7. de Córdoba SR, de Jorge EG. Translational minireview series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008(1);151:1-13.
8. Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremic syndrome. J Exp Med. 2007(6);204:1245-1248. (Pubitemid 46919860)
9. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005(5);16:1392-1403. (Pubitemid 41716523)
10. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006(14);355:1474-1485.
11. Saunders RE, Abarrategui-Garrido C, Frémeaux- Bacchi V, et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat. 2007(3);28:222-234. (Pubitemid 46309972)
12. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PloS Genet. 30041(2007);3:e41. (Pubitemid 46535756)
13. Hughes AE, Orr N, Esfandiary H, et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006; 38(10):1173-1177. (Pubitemid 44470363)
14. Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512-1514. (Pubitemid 351213440)
15. Józsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007;110(5):1516-1518. (Pubitemid 47443967)
16. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008;111(11):5307-5315.
17. Skerka C, Horstmann RD, Zipfel PF. Molecular cloning of a human serum protein structurally related to complement factor H. J Biol Chem. 1991; 266(18):12015-12020. (Pubitemid 21907050)
18. Schwaeble W, Feifel E, Estaller C, et al. Human complement factor H: molecular cloning and cDNA expression reveals variability in the factor H-related mRNA species of 1.4 kb. Immunobiology. 1991;182(3-4):307-322.
19. Park CT, Wright SD. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem. 1996;271(30):18054-18060.
20. Timmann C, Leippe M, Horstmann RD. Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J Immunol. 1991;146(4):1265-1270.
21. Heinen S, Sanchez-Corral P, Jackson MS, et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat. 2006;27(3):292-293.
22. Oppermann M, Manuelian T, Józsi M, et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol. 2006;144(2):342-352.
23. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003; 111(8):181-190. (Pubitemid 36519935)
24. Skerka C, Lauer N, Weinberger AA, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol. 2007;44(13):3398-3406. (Pubitemid 46678196)
25. Lehmann, EH. Nonparametrics: Statistical Methods based on Ranks. San Francisco, CA; Holden Day: 1975;233.
26. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol. 2002;169(9): 4702-4706.
27. Heinen S, Józsi M, Hartmann A, et al. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. J Am Soc Nephrol. 2007;18(2):506-514. (Pubitemid 46193316)
28. Zipfel PF, Skerka C. Complement factor H related proteins in immune diseases. Vaccine. 2008; 26(8):109-114.
29. Male DA, Ormsby RJ, Ranganathan S, Giannakis E, Gordon DL. Complement factor H: sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes. Mol Immunol. 2000(1-2);37:41-52. (Pubitemid 30316193)
30. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement: kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem. 1998;273(27):16828-16835. (Pubitemid 28311711)
31. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res. 2007;37(3):161-175. (Pubitemid 47577440)
32. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-852.
33. Jenne DE, Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci. 1992;4(4):154-159.
34. Podack ER, Preissner KT, Müller-Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl. 1984;284:89-96.
35. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, Zipfel PF. Gpm1p is a factor H-, FHL-1-, and plasminogenbinding surface protein of Candida albicans. J Biol Chem. 2007;282(52): 37537-37544.
36. Behnsen J, Hartmann A, Schmaler J, Gehrke A, Brakhage AA, Zipfel PF. The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun. 2008;76(2):820-827. (Pubitemid 351251755)
37. Kunert A, Losse J, Gruszin C, et al. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol. 2007;179(5):2979-2988.
38. Józsi M, Heinen S, Sanchez-Corral P, et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol. 2006;17(1):170-177.
39. Sethi S, Garnez JD, Vrana JA, et al. Glomeruli of Dense Deposite Disease contain components of the alternative and terminal complement pathway. Kidney Int. 2009;75(9):952-960.